首页 / 院系成果 / 成果详情页

EAC): 5-year (y) follow-up of Chinese pts from CheckMate 649. 会议论文 期刊论文

编号：

B3F6BF0C835AD2CC1E6C313EC297E601
作者：

Shen, Lin ;Bai, Yuxian ;Lin, Xiaoyan ;Li, Wei ;Wang, Jufeng ;Zhang, Xiaochun ;Pan, Hongming ;Bai, Chunmei ;Bai, Li ;Cheng, Ying ;Zhang, Jingdong ;Zhong, Haijun ;Ba, Yi ;Hu, Wenwei ;Xu, RuiHua ;Guo, Weijian ;Qin, Shukui ;Hu, Nan ;McCraith, Stephen ;Liu, Tianshu
作者单位：

Beijing Canc Hosp, Beijing, Peoples R China.
Harbin Med Univ, Affiliated Tumor Hosp, Harbin, Heilongjiang, Peoples R China.
Fujian Med Univ, Union Hosp, Fuzhou, Peoples R China.
First Hosp Jilin Univ, Changchun, Jilin, Peoples R China.
Affiliated Canc Hosp Zhengzhou Univ, Henan Canc Hosp, Zhengzhou, Peoples R China.
Henan Canc Hosp, Zhengzhou, Peoples R China.
Qingdao Univ, Affiliated Hosp, Qingdao, Peoples R China.
Sir Run Run Shaw Hosp, Hangzhou, Peoples R China.
Peking Union Med Coll Hosp, Beijing, Peoples R China.
301 Hosp, Chinese PLA Gen Hosp, Beijing, Peoples R China.
Jilin Canc Hosp, Changchun, Peoples R China.
Liaoning Canc Hosp & Inst, Shenyang, Peoples R China.
Zhejiang Canc Hosp, Dept Med Oncol, Hangzhou, Peoples R China.
Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China.
First Peoples Hosp Changzhou, Changzhou, Peoples R China.
Sun Yat sen Univ, Med Oncol, Guangzhou, Peoples R China.
Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China.
China Pharmaceut Univ, Nanjing Tianyinshan Hosp, Nanjing, Peoples R China.
Bristol Myers Squibb, Princeton, NJ USA.
Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China.
语种：

英文
会议名称：

JOURNAL OF CLINICAL ONCOLOGY
收录：
推荐引用方式
GB/T 7714：

Shen Lin,Bai Yuxian,Lin Xiaoyan, et al. First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up of Chinese pts from CheckMate 649. [J].JOURNAL OF CLINICAL ONCOLOGY,2025,43(4_SUPPL):392-392.
APA：

Shen Lin,Bai Yuxian,Lin Xiaoyan,Li Wei,&Liu Tianshu.(2025).First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up of Chinese pts from CheckMate 649. .JOURNAL OF CLINICAL ONCOLOGY,43(4_SUPPL):392-392.
MLA：

Shen Lin, et al. "First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up of Chinese pts from CheckMate 649." .JOURNAL OF CLINICAL ONCOLOGY 43,4_SUPPL(2025):392-392.
入库时间：

3/5/2025 9:07:53 PM
更新时间：

3/5/2025 9:07:53 PM

浏览次数：8  下载次数：0

分享到：

浏览次数：8

下载次数：0

打印次数：0

First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up of Chinese pts from CheckMate 649. 会议论文 期刊论文

First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up of Chinese pts from CheckMate 649. 会议论文期刊论文